Oncotelic Therapeutics (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
–News Direct–
By Faith Ashmore, Benzinga
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging. OT-101 is the companys lead immuno-oncology drug candidate, showing promise in the treatment of deadly cancers as well as acute COVID-19. It is a first-in-class anti-TGF- RNA therapeutic that inhibits a protein called Transforming Growth Factor Beta (TGF-). TGF- is known to suppress the immune system, help cancer cells evade the immune system and increase the growth and spread of cancer cells.
OT-101 functions by interrupting the production of TGF-, thereby allowing the immune system to recognize and attack cancer cells. In preclinical trials, OT-101 demonstrated strong...